Vivos Reports 7% Sales Drop

Vivos Therapeutics (NASDAQ:VVOS) reported Q2 2025 revenue of $3.8 million, a 7.3% year-over-year decline but exceeding company estimates, as its strategic pivot from dentist-driven sales to direct medical provider alliances, including the Sleep Center of Nevada acquisition, impacted performance. This transition compressed gross margins to 55.0% due to discounting and a shift to lower-margin diagnostic revenue, while operating expenses surged 52% from integration and financing costs. Management views these as expected transition results, but investors face continued uncertainty regarding the pace of direct patient access scaling, conversion of diagnostic revenue to higher-value treatments, gross margin recovery, and persistent liquidity pressures.

Analysis

Vivos Therapeutics (VVOS) is navigating a significant and costly strategic pivot, shifting from a dentist-driven sales model to direct medical provider alliances, headlined by its recent acquisition of The Sleep Center of Nevada (SCN). The financial results from Q2 2025 reflect the disruptive nature of this transition. Revenue declined 7.3% year-over-year to $3.8 million as legacy programs were wound down, though this figure did exceed the company's internal estimate. More concerning are the impacts on profitability and cost structure; gross margin compressed by 10 percentage points to 55.0% due to pricing discounts and a shift toward lower-margin diagnostic revenue. Concurrently, operating expenses surged 52% to $7.0 million, driven by integration and financing costs related to the SCN deal, establishing a structurally higher cost base. While the SCN unit contributed approximately $500,000 in diagnostic revenue in just 20 days post-acquisition, indicating strong underlying patient demand, the company is facing capacity bottlenecks, having served less than 40% of available patients. The reported improvement in GAAP EPS to ($0.55) is misleading as it resulted from an increased share count rather than improved operating performance. The absence of forward guidance from management compounds the uncertainty, leaving investors to weigh the long-term potential of the new model against immediate financial pressures and significant execution risk.

Key Decisions for Investors

• Investors should closely monitor the conversion rate of initial diagnostic revenue from the new sleep centers into higher-value, full-treatment sales, as this is critical to validating the new business model and improving profitability.
• Given the 52% surge in operating expenses and sharp compression in gross margins, it is crucial to scrutinize the company's cash burn rate and liquidity position in the upcoming quarters, as ongoing operating losses present a material financial risk.
• A cautious or neutral stance may be warranted until management provides clear guidance and demonstrates tangible progress in scaling operations and stabilizing margins, as the current results reflect a high-risk transition period with unproven long-term benefits.